Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dominant-negative STAT5 adenovirus
- Development stage
- Discontinued
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
Dn-Stat5 adenovirus (Ad-DN-STAT5) is a recombinant adenoviral vector expressing a dominant-negative mutant of Signal Transducer and Activator of Transcription 5 (STAT5), typically a carboxyl-truncated variant (such as Stat5a-Δ713 or Stat5a-Δ740) that lacks the C-terminal transactivation domain. This construct retains the ability to dimerize and bind DNA but is transcriptionally inactive, thereby acting as a dominant-negative inhibitor of endogenous STAT5a and STAT5b signaling. It is widely used as a research-use-only laboratory tool to investigate the role of STAT5 in cell growth, differentiation, survival, and apoptosis across various models, including breast cancer, prostate cancer, and neuronal systems.
- Other names
- Ad-DN-STAT5Ad-DN-STAT-5Ad-DN-STAT 5Ad-DN-STAT5aAd-DN-STAT-5aAd-DN-STAT 5aAd-DN-STAT5a/bAdStat5aDelta713AdStat-5aDelta713AdStat 5aDelta713AdStat5aDelta740AdStat-5aDelta740AdStat 5aDelta740AdStat5aDelta749AdStat-5aDelta749AdStat 5aDelta749Dn-Stat5 adenovirusDn-Stat-5 adenovirusDn-Stat 5 adenovirusdominant-negative STAT5 adenovirus
02
Targets
STAT5A (STAT5)
Beyond the preview
Go deeper on dominant-negative STAT5 adenovirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dominant-negative STAT5 adenovirus.